Clinical trial
Safety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood…
NCT00419887 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00419887 |
|---|---|
| Title | Safety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood Level of Vildagliptin in Healthy Chinese Volunteers |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Time-Lagged, Parallel-Group, Ascending Single and Multiple Oral Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LAF237 in Chinese Healthy Subjects |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | Vildagliptin (LAF237) |
| Enrollment | 60 |
| Start date | Sep 1, 2006 |
| First posted | Jan 9, 2007 |
| Last update posted | Jun 22, 2007 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: